Kadmon Holdings Inc (NASDAQ:KDMN) CEO Harlan Waksal purchased 2,000 shares of the company’s stock in a transaction on Monday, November 14th. The shares were purchased at an average cost of $6.79 per share, with a total value of $13,580.00. Following the purchase, the chief executive officer now owns 100,040 shares of the company’s stock, valued at $679,271.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Shares of Kadmon Holdings Inc (NASDAQ:KDMN) opened at 6.37 on Wednesday. Kadmon Holdings Inc has a 1-year low of $4.44 and a 1-year high of $10.48. The stock has a 50 day moving average price of $6.28 and a 200-day moving average price of $7.86. The company’s market cap is $287.15 million.

Kadmon Holdings (NASDAQ:KDMN) last announced its earnings results on Wednesday, November 9th. The company reported ($4.23) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by $3.83. The company earned $5.70 million during the quarter, compared to the consensus estimate of $3.90 million. The company’s revenue was down 49.6% compared to the same quarter last year. Equities research analysts forecast that Kadmon Holdings Inc will post ($10.63) earnings per share for the current year.

Insider Buying and Selling by Quarter for Kadmon Holdings (NASDAQ:KDMN)

Institutional investors have recently made changes to their positions in the company. BlackRock Institutional Trust Company N.A. bought a new position in shares of Kadmon Holdings during the third quarter worth approximately $129,000. California State Teachers Retirement System bought a new position in shares of Kadmon Holdings during the third quarter worth approximately $126,000. Beach Point Capital Management LP bought a new position in shares of Kadmon Holdings during the third quarter worth approximately $1,480,000. Morgan Stanley bought a new position in shares of Kadmon Holdings during the third quarter worth approximately $2,180,000. Finally, KCG Holdings Inc. bought a new position in shares of Kadmon Holdings during the third quarter worth approximately $102,000.

Several brokerages have issued reports on KDMN. JMP Securities began coverage on Kadmon Holdings in a research note on Monday, August 22nd. They set an “outperform” rating and a $16.00 price target for the company. WBB Securities began coverage on Kadmon Holdings in a research note on Monday, August 1st. They set a “sell” rating and a $7.50 price target for the company. Jefferies Group began coverage on Kadmon Holdings in a research note on Monday, August 22nd. They set a “buy” rating and a $12.00 price target for the company. HC Wainwright began coverage on Kadmon Holdings in a research note on Monday, August 22nd. They set a “buy” rating and a $25.00 price target for the company. Finally, Citigroup Inc. began coverage on Kadmon Holdings in a research note on Monday, August 22nd. They set a “neutral” rating and a $12.00 price target for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $14.10.

About Kadmon Holdings

Kadmon Holdings, Inc, formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

5 Day Chart for NASDAQ:KDMN

Receive News & Stock Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related stocks with our FREE daily email newsletter.